Ann: Investor Call - 8am AWST - Wednesday 12 August 2020, page-14

Some (non-scientific) points I picked up on this morning:
1. Results of rabbit tox studies available in Q4.
2. Efficacy readouts from patient derived models available late Q4.
3. Second eye drug to be introduced this year H2. 3rd drug also in pipeline.
4. Orphan Drug application has been submitted and decision due by end Sept. This has the potential for significant reimbursement of development costs and reduction of approval timeframes.
5. Both rabbit AND monkey efficacy studies available within 6 months.

Comment by Prof Sue Fletcher - We are very excited, we have never had an opportunity to work with such a high quality CPP before.

Looks like a good flow of news in the coming months - starting late September.
I've upgraded from Hold to Buy, due to the range of developments due in short term (orphan drug, 2nd drug, rabbits, efficacy readouts, monkeys) which I anticipate will deliver mostly positive outcomes. I have no idea which way the orphan drug application will swing, but if it is positive then that will be fantastic news. I have been surprised in recent months with the length of the IND approval process. I thought 6-12 months not 12-18. hopefully the orphan drug application can take us closer to 12 months.

Hope this makes sense and is accurate - if anyone else can add or improve this update then please do so.
Timbo